4-methylmorpholine acetate | 144505-55-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 英文名称: 4-methylmorpholine acetate
• 英文别名: 4-Methylmorpholin-4-ium;acetate
• CAS: 144505-55-5
• 化学式: C₂H₄O₂*C₅H₁₁NO
• 分子量: 161.201
• InChiKey: MUTXDFGBERJZBX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.04
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  49.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  N-甲基吗啉 、 溶剂黄146 反应 24.0h， 生成 4-methylmorpholine acetate
  参考文献：
  名称：

  质子吗啉基离子液体表面性质的实​​验研究

  摘要：

  在这项工作中，合成了十种具有烷基羧酸根阴离子的新型质子吗啉基离子液体（ILs），其密度和表面张力的测量范围为298.15至348.15K。该设备有助于在水含量极低且没有水蒸气的情况下在液/气界面进行测量。在相同条件下也测量了弯液面接触角。每个IL的表面张力表现出与温度的高度线性相关性，从而可以准确评估表面热力学函数（表面熵和表面能）。根据表面张力值，通过古根希姆（Guggenhiem）和Eötvös方程估算临界点。表面张力，

  DOI：

  10.1016/j.molliq.2017.06.045
• 作为试剂：
  描述：

  2-dibromo<1-(13)C>-ethanol 、 腺苷 在 4-methylmorpholine acetate 作用下， 反应 144.0h， 以4%的产率得到
  参考文献：
  名称：

  Formation of etheno adducts of adenosine and cytidine from 1-halooxiranes. Evidence for a mechanism involving initial reaction with the endocyclic nitrogen atoms

  摘要：

  The etheno derivatives of nucleic acid bases contain an additional ring and are of interest because of their useful fluorescence properties and their potential as mutagenic lesions in DNA. The mechanism of formation from 2-haloacetaldehydes is known to involve initial Schiff base formation at an exocyclic nitrogen; however, mechanisms of formation from the more relevant 1-substituted oxiranes have not been established. The reaction of N6-methyladenosine (5) with 1-chlorooxirane yielded the stable carbinolamine 7,8-dihydro-8-hydroxy-9-methyl-3-beta-D-ribofuranosylimidazo[2,1-i]purinium species (10), consistent with initial attack of the N1 atom of adenine at the methylene of 1-chlorooxirane. No products indicative of initial reaction at the N6 atom of adenine were found. Reaction of 2,2-dibromoethanol with adenosine or cytidine at pH 9.2 yielded 1,N6-ethenoadenosine (1) or 3,N4-ethenocytidine (2), respectively, presumably via the base-catalyzed formation of 1-bromooxirane from the bromohydrin. When reactions were done with 2,2-dibromo[1-C-13]ethanol, 1 contained label only at C-7 and 2 contained label only at C-3. A role for 2-bromoacetaldehyde in these reactions was ruled out by the lack of incorporation of deuterium from (H2O)-H-2 into 1 under conditions where the exchange of the methylene protons of 2-bromoacetaldehyde with the solvent was relatively rapid. The collective results are most consistent with a mechanism in which the basic endocyclic nitrogen (N1 of adenine or N3 of cytosine) reacts with the methylene carbon of the 1-halooxirane, and, after ring opening and loss of the leaving group, the resulting aldehyde reacts with the exocyclic nitrogen to form the additional ring.

  DOI：

  10.1021/ja00029a041

文献信息

• An experimental study on the surface properties of Protic Morpholinium-based ionic liquids
  作者：Mohammad Hadi Ghatee、Tahereh Ghaed-sharaf

  DOI：10.1016/j.molliq.2017.06.045

  日期：2017.9

  In this work, ten novel protic morpholinium-based ionic liquids (ILs) with alkyl-carboxylate anion were synthesized and their densities and surface tensions were measured in the range 298.15 to 348.15 K. Surface tension was measured by capillary rise method, while the capillary apparatus facilitates measurement at liquid/vapor interface with very low water content and in the absence of water vapor

  在这项工作中，合成了十种具有烷基羧酸根阴离子的新型质子吗啉基离子液体（ILs），其密度和表面张力的测量范围为298.15至348.15K。该设备有助于在水含量极低且没有水蒸气的情况下在液/气界面进行测量。在相同条件下也测量了弯液面接触角。每个IL的表面张力表现出与温度的高度线性相关性，从而可以准确评估表面热力学函数（表面熵和表面能）。根据表面张力值，通过古根希姆（Guggenhiem）和Eötvös方程估算临界点。表面张力，
• [EN] NEW SUBSTITUTED CYANOINDOLINE DERIVATIVES AS NIK INHIBITORS<br/>[FR] NOUVEAUX DÉRIVÉS DE CYANOINDOLINE UTILISÉS COMME INHIBITEURS DE NIK
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2017125530A1

  公开（公告）日：2017-07-27

  The present invention relates to pharmaceutical agents of formula (I) useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF- KB-inducing kinase (NIK - also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.

  本发明涉及一种公式（I）的药物制剂，用于治疗和/或预防哺乳动物中的疾病，特别是用于治疗癌症、炎症性疾病、代谢性疾病和自身免疫性疾病的NF-KB诱导激酶（NIK，也称为MAP3K14）的抑制剂。该发明还涉及包含这些化合物的药物组合物，以及利用这些化合物或药物组合物预防或治疗癌症、炎症性疾病、包括肥胖和糖尿病在内的代谢性疾病以及自身免疫性疾病的用途。
• Understanding the behavior of mixtures of protic-aprotic and protic-protic ionic liquids: Conductivity, viscosity, diffusion coefficient and ionicity
  作者：Sachin Thawarkar、Nageshwar D. Khupse、Dinesh R. Shinde、Anil Kumar

  DOI：10.1016/j.molliq.2018.12.024

  日期：2019.2

  We have investigated the physicochemical properties such as electrical conductivity, viscosity and diffusion coefficient for the binary mixtures of protic ionic liquids with aprotic ionic liquids and of protic with protic ionic liquids at 298.15 K. A significant enhancement in the electrical conductivity is observed for the binary mixtures of ionic liquids, as compared to those of the constituent pure

  我们已经研究了质子离子液体与非质子离子液体以及质子与质子离子液体在298.15 K下的二元混合物的物理化学性质，例如电导率，粘度和扩散系数。与构成纯离子液体的离子液体相比，离子液体的混合物随混合物的组成而变化。质子与质子惰性离子液体，1-丁基-3-甲基咪唑鎓双（三氟甲基磺酰基）酰亚胺[bmIm] [NTf 2 ]，1-丁基-1-甲基吡咯烷双（三氟甲基磺酰基）酰亚胺[bmPyrr] [NTf 2 ]的二元混合物的粘度1,3-二甲基咪唑硫酸甲酯，[mmIm] [CH 3 SO 4]随着[HmIm] [CH 3 COO]的组成的增加而降低。相反，当添加1-甲基咪唑乙酸盐时，质子与质子离子液体，1-甲基吡咯乙酸乙酸盐[HmPyrr] [CH 3 COO]和4-甲基吗啉乙酸盐[HmMorph] [CH 3 COO]的二元混合物的粘度增加[HmIm] [CH 3 COO]。使用脉冲梯度自旋回波（PGS
• Specific human antibodies
  申请人：Levanon Avigdor

  公开号：US20050152906A1

  公开（公告）日：2005-07-14

  The present invention provides antibodies that bind an epitope of PSGL-1 comprising the motif D-X-Y-D, wherein X represents any amino acid or the covalent linkage between D and Y, and Y is sulfated, which antibody can be complexed with one or more copies of an agent. The antibodies of the invention can be used in a method of inducing antibody-dependent cell cytotoxicity and/or stimulating natural killer (NK) cells or T cells. In addition, by administering these antibodies to a patient in need thereof, a method of inducing cell death is provided. A method of preventing infection by a virus (e.g., HIV) by administering to a patient in need thereof an antibody of the present invention is also provided. The, present invention also provides a method of introducing an agent into a cell that expresses sulfated PSGL-1 by coupling or complexing an agent to an antibody of the present invention and administering the complex to the cell. Finally, the present invention provides methods of diagnosis, prognosis and staging using the present antibodies.

  本发明提供一种与PSGL-1表位结合的抗体，该表位包括D-X-Y-D基序，其中X代表任何氨基酸或D和Y之间的共价键，Y为磺酸化。该抗体可以与一种或多种药剂形成复合物。本发明的抗体可用于诱导抗体依赖性细胞毒性和/或刺激自然杀伤细胞或T细胞的方法。此外，通过将这些抗体给予需要的患者，提供了一种诱导细胞死亡的方法。本发明还提供了一种通过给予本发明的抗体治疗病人，预防病毒感染（例如HIV）的方法。最后，本发明提供了一种通过将药剂与本发明的抗体耦合或复合并将复合物给予表达磺酸化PSGL-1的细胞的方法。本发明还提供了使用本发明的抗体进行诊断、预后和分期的方法。
• [EN] LIPOPEPTIDES AS ANTIBACTERIAL AGENTS<br/>[FR] LIPOPEPTIDES UTILES EN TANT QU'AGENTS ANTIBACTERIENS
  申请人：CUBIST PHARM INC

  公开号：WO2001044274A1

  公开（公告）日：2001-06-21

  The present invention relates to novel lipopeptide compounds. The invention also relates to pharmaceutical compositions of these compounds and methods of using these compounds as antibacterial compounds. The invention also relates to methods of producing these novel lipopeptide compounds and intermediates used in producing these compounds.

  本发明涉及新型脂肽化合物。本发明还涉及这些化合物的药物组合物和将这些化合物用作抗菌化合物的方法。本发明还涉及制备这些新型脂肽化合物和用于制备这些化合物的中间体的方法。